NASDAQ:THTX Theratechnologies (THTX) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free THTX Stock Alerts $1.30 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.30▼$1.3750-Day Range$1.18▼$1.7052-Week Range$0.88▼$4.30Volume12,885 shsAverage Volume61,692 shsMarket Capitalization$31.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Theratechnologies alerts: Email Address Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Theratechnologies Stock (NASDAQ:THTX)Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.Read More THTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart THTX Stock News HeadlinesApril 15, 2024 | globenewswire.comTheratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of ShareholdersApril 11, 2024 | seekingalpha.comTheratechnologies Inc. (THTX) Q1 2024 Earnings Call TranscriptApril 26, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 11, 2024 | globenewswire.comTheratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 10, 2024 | investorplace.comTHTX Stock Earnings: Theratechnologies Beats EPS, Misses Revenue for Q1 2024April 10, 2024 | globenewswire.comTheratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024April 10, 2024 | globenewswire.comTheratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024April 8, 2024 | globenewswire.comTheratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology PlatformApril 26, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 5, 2024 | globenewswire.comTheratechnologies Appoints Elina Tea to its Board of DirectorsApril 3, 2024 | globenewswire.comTheratechnologies to Announce First Quarter 2024 Financial Results and Provide Business UpdateMarch 30, 2024 | stockhouse.comTheratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology(TM) PlatformMarch 28, 2024 | globenewswire.comTheratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ PlatformMarch 24, 2024 | investing.comTheratechnologies shifts focus, phases down preclinical researchMarch 22, 2024 | globenewswire.comTheratechnologies Announces Update on its Preclinical Oncology Research ProgramMarch 21, 2024 | globenewswire.comTheratechnologies Appoints Jordan Zwick to its Board of DirectorsMarch 21, 2024 | globenewswire.comTheratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerFebruary 29, 2024 | globenewswire.comTheratechnologies Announces the Resignation of One of Its Directors, Mr. Alain TrudeauFebruary 27, 2024 | globenewswire.comTheratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDAFebruary 21, 2024 | washingtonpost.comTheratechnologies: Fiscal Q4 Earnings SnapshotFebruary 21, 2024 | globenewswire.comTheratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 GuidanceFebruary 20, 2024 | globenewswire.comTheratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of ActionFebruary 15, 2024 | finance.yahoo.comTheratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerFebruary 15, 2024 | globenewswire.comTheratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerJanuary 23, 2024 | finance.yahoo.comTheratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License ApplicationJanuary 19, 2024 | msn.comUpcoming FDA Decision: How likely is approval for EGRIFTA MDV?January 6, 2024 | theglobeandmail.comWill This Dual-Listed Bio-Pharma Catch New Year Action?See More Headlines Receive THTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today4/26/2024Next Earnings (Estimated)7/10/2024Fiscal Year End11/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:THTX CUSIPN/A CIK1512717 Webwww.theratech.com Phone(514) 336-7800Fax514-331-9691Employees103Year Founded1993Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,960,000.00 Net Margins-23.04% Pretax Margin-22.48% Return on EquityN/A Return on Assets-26.15% Debt Debt-to-Equity RatioN/A Current Ratio1.15 Quick Ratio1.03 Sales & Book Value Annual Sales$81.76 million Price / Sales0.38 Cash FlowN/A Price / Cash FlowN/A Book Value($1.02) per share Price / Book-1.27Miscellaneous Outstanding Shares24,200,000Free FloatN/AMarket Cap$31.46 million OptionableOptionable Beta1.34 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Philippe Dubuc M.B.A. (Age 57)MBA, Senior VP & CFO Comp: $432.31kMr. Jocelyn Lafond L.L.M. (Age 56)LL.B., General Counsel & Corporate Secretary Comp: $316.29kDr. Christian Marsolais Ph.D. (Age 61)Senior VP & Chief Medical Officer Comp: $434.61kMr. John Leasure (Age 59)Global Commercial Officer Comp: $420.91kHon. Andre Dupras M.Sc. (Age 60)Vice President of Human Resources Key CompetitorsCASI PharmaceuticalsNASDAQ:CASIAcurx PharmaceuticalsNASDAQ:ACXPVYNE TherapeuticsNASDAQ:VYNEImmunoPrecise AntibodiesNASDAQ:IPAViracta TherapeuticsNASDAQ:VIRXView All CompetitorsInstitutional OwnershipSummit Trail Advisors LLCBought 33,090 shares on 4/23/2024Ownership: 0.137%AIGH Capital Management LLCBought 2,915,906 shares on 2/12/2024Ownership: 15.368%Worth Venture Partners LLCBought 710,551 shares on 2/9/2024Ownership: 3.746%Wealthspire Advisors LLCBought 51,250 shares on 2/7/2024Ownership: 0.212%Bare Financial Services IncBought 23,907 shares on 2/6/2024Ownership: 0.099%View All Institutional Transactions THTX Stock Analysis - Frequently Asked Questions Should I buy or sell Theratechnologies stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" THTX shares. View THTX analyst ratings or view top-rated stocks. How have THTX shares performed in 2024? Theratechnologies' stock was trading at $1.62 at the beginning of 2024. Since then, THTX stock has decreased by 19.8% and is now trading at $1.30. View the best growth stocks for 2024 here. Are investors shorting Theratechnologies? Theratechnologies saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 24,100 shares, an increase of 94.4% from the March 31st total of 12,400 shares. Based on an average trading volume of 49,100 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.1% of the company's shares are sold short. View Theratechnologies' Short Interest. When is Theratechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 10th 2024. View our THTX earnings forecast. How were Theratechnologies' earnings last quarter? Theratechnologies Inc. (NASDAQ:THTX) announced its quarterly earnings data on Wednesday, February, 21st. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.16. The firm had revenue of $23.45 million for the quarter. During the same quarter in the prior year, the firm earned ($0.36) earnings per share. When did Theratechnologies' stock split? Shares of Theratechnologies reverse split before market open on Monday, July 31st 2023. The 1-4 reverse split was announced on Monday, July 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What guidance has Theratechnologies issued on next quarter's earnings? Theratechnologies updated its FY 2024 earnings guidance on Thursday, April, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $87.0 million-$90.0 million, compared to the consensus revenue estimate of $88.2 million. What other stocks do shareholders of Theratechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Trevena (TRVN), Citius Pharmaceuticals (CTXR), Great Panther Mining (GPL), TherapeuticsMD (TXMD), Advanced Micro Devices (AMD), Bionano Genomics (BNGO), ChromaDex (CDXC), Caladrius Biosciences (CLBS) and Chimerix (CMRX). Who are Theratechnologies' major shareholders? Theratechnologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include Summit Trail Advisors LLC (0.14%). How do I buy shares of Theratechnologies? Shares of THTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Theratechnologies have any subsidiaries? The following companies are subsidiares of Theratechnologies: Katana, Pharma-G Inc., Theratechnologies Europe Inc., Theratechnologies Europe Limited, Theratechnologies Intercontinental Inc., and Theratechnologies U.S. Inc.Read More This page (NASDAQ:THTX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
